Publicacións (22) Publicacións de Juan Jose Cerezo Manchado

2023

  1. Congenital factor XI deficiency and risk of heart failure in humans

    Journal of Thrombosis and Haemostasis

  2. Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation

    Clinical and Applied Thrombosis/Hemostasis, Vol. 29

  3. Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry

    Clinical and Applied Thrombosis/Hemostasis, Vol. 29

  4. Impact of atrial fibrillation and anticoagulation on the risk of death, thromboembolic disease and bleeding in patients with COVID-19: the ACO-VID Registry

    Current Medical Research and Opinion, Vol. 39, Núm. 6, pp. 811-817

2022

  1. Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: An update of the ANIBAL*protocol

    Drugs in Context, Vol. 11

  2. Safety and effectiveness of edoxaban in clinical practice after one year of follow-up in Spain. The ETNA-AF-EUROPE registry

    REC: CardioClinics, Vol. 57, Núm. 1, pp. 39-47

2021

  1. Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity

    IJC Heart and Vasculature, Vol. 37

  2. Treatment preferences as basis for decision making in patients using direct oral anticoagulants in Spain

    Journal of Thrombosis and Thrombolysis, Vol. 51, Núm. 2, pp. 475-484

2020

  1. Aortic valve stenosis provides complementary information to bleeding risk scores in non-valvular atrial fibrillation patients initiating anticoagulation

    Journal of Geriatric Cardiology, Vol. 17, Núm. 3, pp. 141-148

  2. Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: The anibal protocol

    Drugs in Context, Vol. 9, pp. 1-12

  3. Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry

    Future Cardiology, Vol. 16, Núm. 5, pp. 469-480

2019

  1. Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists

    European Journal of Clinical Investigation, Vol. 49, Núm. 10

  2. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry

    Current Medical Research and Opinion, Vol. 35, Núm. 8, pp. 1463-1471

  3. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: Outcomes from the first observational and prospective study in a Spanish population

    Journal of Comparative Effectiveness Research, Vol. 8, Núm. 3, pp. 165-178

  4. Prevalence and Prognostic Implications of Valve Disease in Patients With Atrial Fibrillation Initiating Direct Oral Anticoagulants

    Revista Espanola de Cardiologia, Vol. 72, Núm. 11, pp. 935-943

  5. Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry

    Current Medical Research and Opinion, Vol. 35, Núm. 12, pp. 2035-2041

2018

  1. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke

    Future Cardiology, Vol. 14, Núm. 3s, pp. 31-37

  2. Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation

    European Journal of Clinical Investigation, Vol. 48, Núm. 6

2016

  1. Genotype-guided therapy improves initial acenocoumarol dosing: Results from a prospective randomised study

    Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 117-125

2014

  1. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment

    Pharmacogenomics, Vol. 15, Núm. 7, pp. 987-996